EXOSOMES: ROLE IN ALLOGRAFT REJECTION AND POTENTIAL AS A BIOMARKER
外泌体:在同种异体移植排斥中的作用以及作为生物标志物的潜力
基本信息
- 批准号:9007346
- 负责人:
- 金额:$ 21.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-15 至 2018-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAntibodiesAreaBindingBiological MarkersBiopsyBiopsy SpecimenBlood CirculationBody FluidsBronchiolitisBronchiolitis ObliteransBronchoalveolar Lavage FluidCell TransplantsCellsCharacteristicsChronicChronic Obstructive Airway DiseaseClassificationClinicalCollagenConsensusCystic FibrosisDataDetectionDevelopmentDiagnosisDiagnosticDiseaseEndothelial CellsEpithelialEpithelial CellsEvaluationEventExtracellular Matrix ProteinsFibrosisGene ExpressionGoalsGoldHamman-Rich syndromeHealthHistologicHumanImmuneImmune responseInterobserver VariabilityIntraobserver VariabilityKineticsLeadLesionLeukocytesLungLung TransplantationLung diseasesLymphocyteMeasurementMediatingMessenger RNAMethodsMicroRNAsMolecular ProfilingOrganOrgan TransplantationPathologyPhenotypeProteinsReaderRegulationResistanceRoleSerumSiteSpirometryStagingStructure of parenchyma of lungStructure of respiratory bronchioleSyndromeTerminal BronchioleTestingTransplant RecipientsUltracentrifugationallograft rejectionbasediagnosis standardexosomeimprovedinsightlung allograftmouse modelnovel markerpotential biomarkerresearch studyselective expressionspecific biomarkers
项目摘要
DESCRIPTION (provided by applicant): Lung transplantation (LTx) is a viable treatment option for end-stage lung diseases. Although short-term survival has improved, acute and chronic rejection remains as hurdles for long-term function of the organ. Diagnosis of both acute and chronic rejection following human LTx remains an important challenge. Transbronchial lung biopsy has been the gold standard for the diagnosis of acute rejection. However, there is significant interobserver variability, and up to 40% of biopsies are insufficient for evaluation of
rejection. Diagnostic features for Ab mediated rejection also varies widely. Lastly, chronic rejection after LTx is characterized histologically by obliterative bronchiolitis (OB), a fibroproliferative lesion involving terminal and respiratory bronchioles. Transbronchial lung biopsy is an insensitive method for the detection of OB. Therefore, chronic lung allograft rejection is diagnosed and staged according to decrements in spirometry measurements, a downstream event that induces airway fibrosis and obliteration. Therefore, further insights into the mechanisms of rejection and identifying specific biomarkers for rejection after LTx is critical
for long term function of the transplanted lungs. Using both human LTxR and a murine model of chronic rejection, obliterataive airway disease (OAD), we demonstrated that: 1) In human LTxR, circulating exosomes are detectable during acute cellular rejection (A1 and A2). 2) Exosomes can be detected in the sera earlier to acute cellular rejection. 3) De novo development of DSA is accompanied by exosomes in the bronchoalveolar lavage fluid (BAL). 4) Exosomes contained Collagen V (Col-V) which has been shown to be selectively expressed in the lung parenchyma. 5) Exosomes are present in the local site (BAL) much before clinical evidences of OAD lesions, and 6) Sera from LTxR diagnosed with BOS also have Col-V containing exosomes which are detectable in the sera much before BOS. Based on these findings, we propose to determine; 1) The mechanisms by which exosome induction following donor specific immune responses lead to lung allograft rejection; and 2) Determine the kinetics of exosome development with the goal to employ exosome detection in the sera as a potential biomarker for rejection and treatment of rejection. Towards this, we will determine the kinetics of exosomes present in the BAL and serum following LTx using ultracentrifugation and protein isolation methods and correlate the findings with acute cellular, acute Ab mediated, and chronic rejection. Subsequent experiments will; a) define the composition of exosomes; b) determine the cells contributing to the exosome; and c) determine whether HLA specific messenger RNA (mRNA) present in the exosomes will transfer the donor HLA to recipient epithelial and endothelial cells. This is based on our premise that the exosomes will contain several microRNAs involved in immune regulation and donor HLA mRNA. Further, mRNA for HLA in the exosomes may transfer the message to the recipient's epithelial or endothelial cells leading to continued immune responses against the donor HLA resulting in chronic rejection following human LTx.
描述(由申请人提供):肺移植(LTx)是终末期肺病的可行治疗选择。尽管短期生存有所改善,但急性和慢性排斥反应仍然是器官长期功能的障碍。人类 LTx 后急性和慢性排斥反应的诊断仍然是一个重要的挑战。经支气管肺活检一直是诊断急性排斥反应的金标准。然而,观察者之间存在显着差异,高达 40% 的活检不足以评估
拒绝。 Ab 介导的排斥反应的诊断特征也有很大差异。最后,LTx 后的慢性排斥在组织学上以闭塞性细支气管炎 (OB) 为特征,这是一种累及终末细支气管和呼吸细支气管的纤维增殖性病变。经支气管肺活检是一种不敏感的 OB 检测方法。因此,慢性肺同种异体移植排斥反应是根据肺活量测量的减少来诊断和分期的,肺活量测量是诱导气道纤维化和闭塞的下游事件。因此,进一步深入了解 LTx 后的排斥机制并确定排斥反应的特定生物标志物至关重要
为了移植肺的长期功能。使用人类 LTxR 和慢性排斥、闭塞性气道疾病 (OAD) 的小鼠模型,我们证明:1) 在人类 LTxR 中,在急性细胞排斥期间可检测到循环外泌体(A1 和 A2)。 2) 可以在急性细胞排斥反应发生之前在血清中检测到外泌体。 3)DSA的从头发育伴随着支气管肺泡灌洗液(BAL)中的外泌体。 4) 外泌体含有 V 型胶原蛋白 (Col-V),已被证明在肺实质中选择性表达。 5) 外泌体早在 OAD 病变的临床证据之前就存在于局部部位 (BAL),并且 6) 来自诊断为 BOS 的 LTxR 的血清也含有含有 Col-V 的外泌体,这些外泌体早在 BOS 之前就可以在血清中检测到。根据这些发现,我们建议确定; 1)供体特异性免疫反应后外泌体诱导导致肺同种异体移植排斥的机制; 2) 确定外泌体发育动力学,目标是利用血清中的外泌体检测作为排斥反应和排斥反应治疗的潜在生物标志物。为此,我们将使用超速离心和蛋白质分离方法确定 LTx 后 BAL 和血清中存在的外泌体的动力学,并将这些结果与急性细胞、急性 Ab 介导的和慢性排斥反应相关联。随后的实验将; a) 定义外泌体的组成; b) 确定对外泌体有贡献的细胞; c) 确定外泌体中存在的 HLA 特异性信使 RNA (mRNA) 是否会将供体 HLA 转移至受体上皮细胞和内皮细胞。这是基于我们的假设,即外泌体将含有几种参与免疫调节的 microRNA 和供体 HLA mRNA。此外,外泌体中 HLA 的 mRNA 可能会将信息传递给受体的上皮或内皮细胞,导致针对供体 HLA 的持续免疫反应,从而导致人类 LTx 后的慢性排斥反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THALACHALLOUR MOHANAKUMAR其他文献
THALACHALLOUR MOHANAKUMAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THALACHALLOUR MOHANAKUMAR', 18)}}的其他基金
Chronic Lung Allograft Dysfunction: Role for Tumor Suppressor LKB1 in Exosomes
慢性肺同种异体移植功能障碍:肿瘤抑制因子 LKB1 在外泌体中的作用
- 批准号:
10516866 - 财政年份:2022
- 资助金额:
$ 21.09万 - 项目类别:
Chronic Lung Allograft Dysfunction: Role for Tumor Suppressor LKB1 in Exosomes
慢性肺同种异体移植功能障碍:肿瘤抑制因子 LKB1 在外泌体中的作用
- 批准号:
10644007 - 财政年份:2022
- 资助金额:
$ 21.09万 - 项目类别:
EXOSOMES: ROLE IN ALLOGRAFT REJECTION AND POTENTIAL AS A BIOMARKER
外泌体:在同种异体移植排斥中的作用以及作为生物标志物的潜力
- 批准号:
9243980 - 财政年份:2016
- 资助金额:
$ 21.09万 - 项目类别:
ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)
MHC 同种抗体可诱发自身免疫和闭塞性气道疾病 (OAD)
- 批准号:
9265488 - 财政年份:2009
- 资助金额:
$ 21.09万 - 项目类别:
ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)
MHC 同种抗体可诱发自身免疫和闭塞性气道疾病 (OAD)
- 批准号:
8269926 - 财政年份:2009
- 资助金额:
$ 21.09万 - 项目类别:
ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)
MHC 同种抗体可诱发自身免疫和闭塞性气道疾病 (OAD)
- 批准号:
8076746 - 财政年份:2009
- 资助金额:
$ 21.09万 - 项目类别:
ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)
MHC 同种抗体可诱发自身免疫和闭塞性气道疾病 (OAD)
- 批准号:
7737001 - 财政年份:2009
- 资助金额:
$ 21.09万 - 项目类别:
ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)
MHC 同种抗体可诱发自身免疫和闭塞性气道疾病 (OAD)
- 批准号:
7907752 - 财政年份:2009
- 资助金额:
$ 21.09万 - 项目类别:
ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)
MHC 同种抗体可诱发自身免疫和闭塞性气道疾病 (OAD)
- 批准号:
8956978 - 财政年份:2009
- 资助金额:
$ 21.09万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 21.09万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 21.09万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 21.09万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 21.09万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 21.09万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 21.09万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 21.09万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 21.09万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 21.09万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 21.09万 - 项目类别: